NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
NEUROCRINE BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$136.98+1.27 (+0.94%)
Close on Oct 19, 2026
- Market cap
- $14.27B
- P/E (TTM)
- 20.1
- Dividend yield
- –
NEUROCRINE BIOSCIENCES INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $954.30M | $811.00M | $798.30M | $789.90M | $682.00M | $563.70M | $621.20M | $616.60M | $583.80M | $509.00M | $507.20M | $491.80M | 99.5% | +39.9% |
| Collaboration revenues | $4.70M | $3.50M | $7.20M | $5.00M | $5.50M | $8.90M | $6.50M | $5.50M | $6.40M | $6.30M | $8.00M | $7.00M | 0.5% | -14.5% |
By region
From the segment and revenue-disaggregation notes of Neurocrine Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.